Partner

Articles & Insights / Packaging Science

Packaging as a Stability Variable

Packaging influences the environment experienced by a formulation throughout storage and use. Selecting a pack therefore requires evidence about the complete product and closure system, including the way the user opens, handles and dispenses it.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Define the protection the product needs
  • Evaluate the complete system
  • Assess compatibility as well as barrier properties

Define the protection the product needs

Start with sensitivity to moisture, oxygen, light, temperature and interaction with contact materials. A dry tablet that softens after moisture exposure requires a different strategy from an oil that oxidises or a liquid that loses preservative to its container. Describe the failure mechanism before comparing pack options.

For pharmaceuticals, packaging suitability includes protection, compatibility, safety and performance. For foods and nutraceuticals, assess the applicable food-contact, migration and category requirements independently. Pharmaceutical packaging guidance can inform scientific thinking without replacing food regulations. FDA’s newer container-closure document was listed as a draft at the time of preparation; it should be distinguished from the established final guidance. R12R13R14R25

Evaluate the complete system

A resin specification describes one component. The supplied pack also includes geometry, wall thickness, seals, liners, closure application and potential dispensing features. A high-barrier bottle can perform poorly if its closure leaks or is inconsistently applied. Supplier transmission data should therefore be interpreted under the stated test conditions and confirmed where necessary on the actual system.

Avoid comparing water-vapour transmission values obtained with different methods or units as though they are directly interchangeable. Film values expressed per area differ from whole-container measurements expressed per pack. Product exposure also depends on the driving humidity gradient and temperature. The illustration presents the major exposure routes without assigning invented barrier ratings to materials.

Explore the sciencePackaging Science

A closer look inside the pack

BarrierContactHeadspaceUse
Barrier & seals

Assess the actual container, closure application and seal performance together.

Conceptual illustration. Select a topic to explore its role. The visual does not establish formulation performance or prescribe universal regulatory requirements.

Whole-system performance includes barrier properties, closure behaviour, product contact and exposure during use. The drawing is conceptual and not a packaging engineering specification.

Assess compatibility as well as barrier properties

Contact materials can release substances into the product, absorb product components or promote a reaction. A preservative may partition into packaging, while a flavour or lipophilic ingredient may be lost through sorption. Evaluate plausible extractables and leachables risks according to the dosage form, route, contact duration and material composition.

A small compositional change in a liner or colourant can be relevant even when the bottle looks identical. Define the approved packaging specification and supplier change-notification expectations so that the assessed system can be reproduced. Compatibility conclusions should identify which components and product conditions they cover.

Consider headspace and repeated opening

A nitrogen flush may reduce initial headspace oxygen, but continued protection depends on permeation, seal performance and opening. A desiccant has finite capacity and its effectiveness depends on moisture entering the pack and moisture already present in the contents. Neither measure corrects every packaging weakness.

Use patterns can be decisive. A large bottle opened daily for several months may expose the final units differently from an unopened stability sample. An in-use study can simulate opening, withdrawal and reclosing under defined conditions. The simulation should reflect realistic use and identify its assumptions, including the frequency of opening and the number of units removed.

Compare options through a product study

For a hypothetical hygroscopic chewable, compare candidate packs using matched product and storage conditions. Track moisture, texture, assay and relevant impurities. Include closure-application checks so that a favourable result is not attributed solely to the bottle material. Define the attributes that will determine the selection before reviewing the results.

The lowest moisture level is not always the best outcome. Excessive drying can alter some products, and a pack that protects chemistry may be difficult to use. A final choice balances demonstrated protection with dispensing, transport, manufacturability and the intended user’s handling needs.

Manage packaging changes scientifically

A sustainability-driven material change should retain the relevant protection and compatibility evidence. Compostability or biodegradability does not establish food-contact suitability, barrier performance or pharmaceutical compatibility. Compare the new system against the original, identify additional risks and determine the stability and regulatory work needed before implementation.

Stabicon can support product-specific packaging studies that connect material choices to observed stability and use performance. This enables a documented selection based on the formulation’s needs rather than assumptions about a material category.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R01
    ICH Q1A R2 Stability Testing of New Drug Substances and Products

    Final guideline, 2003. Pharmaceutical scope; apply target-authority requirements.

  2. R12
    FDA Container Closure Systems for Packaging Human Drugs and Biologics

    Final guidance, 1999. Distinguish from the newer draft document.

  3. R13
    FDA Container Closure Systems Questions and Answers

    Final guidance, 2002. Companion to the established packaging guidance.

  4. R14
    FSSAI Food Safety Management Systems Guidance for Food Supplements

    Guidance document, 2018. Practical food-supplement manufacturing and hygiene context; not a replacement for current regulations.

  5. R25
    FDA Container Closure Systems for Human Drugs and Biological Products

    Draft guidance, August 2026, as listed when checked. Distinguish draft proposals from final guidance.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin